Bitter gourd (momordica charantia): a dietary approach to hyperglycemia

Auteur(s) :
Krawinkel MB., Keding GB.
Date :
Juil, 2006
Source(s) :
Nutrition reviews. #64;7 p331-337
Adresse :
Addresses: Krawinkel MB (reprint author), Univ Giessen, Inst Nutr Sci, Dept Int Nutr, Wilhelmstr 20, D-35392 Giessen Germany Univ Giessen, Inst Nutr Sci, Dept Int Nutr, D-35392 Giessen Germany E-mail Addresses: Publisher: INT LIFE SCIENCES INST NORTH AMERICA, ONE THOMAS CIRCLE, N W, 9TH FLOOR, WASHINGTON, DC 20005 USA, Discipline: FOOD SCIENCE/NUTRITION ENDOCRINOLOGY, NUTRITION & METABOLISM CC Editions/Collections: Agriculture, Biology & Environmental Sciences (ABES); Life Sciences (LS) IDS Number: 068VG

Sommaire de l'article

Abstract: Bitter gourd (Momordica charantia) is a vegetable with pantropical distribution. It contains substances with antidiabetic properties such as charantin, vicine, and polypeptide-p, as well as other unspecific bioactive components such as antioxidants. Metabolic and hypoglycemic effects of bitter gourd extracts have been demonstrated in cell culture, animal, and human studies. The mechanism of action, whether it is via regulation of insulin release or altered glucose metabolism and its insulin-like effect, is still under debate. Adverse effects are also known. Nevertheless, bitter gourd has the potential to become a component of the diet or a dietary supplement for diabetic and prediabetic patients. Well-designed interdisciplinary research by nutritionists, medical doctors, and agronomists is needed before a dietary recommendation can be given and a product brought to the market.

Source : Pubmed